The Institute for Clinical and Economic Review in an evidence report suggests three therapies used to combat hereditary angioedema (HAE) attacks yield positive health impacts, but at a high cost.
Per a press release from ICER, the report assessed Shire Plc’s lanadelumab and two C1 inhibitors: CSL Behring GmbH’s Haegarda and Shire Plc’s Cinryze.
“While long-term prophylaxis with all three therapies resulted in fewer acute attacks and improved quality of life for people living with hereditary angioedema, these improvements come at a substantial financial cost,” ICER Chief Medical Officer David Rind said. “At their current prices, these treatments do not meet traditional cost-effectiveness thresholds.”
ICER in its report says the drugs “far exceed” common quality-adjusted life year thresholds of $50,000-$150,000. Below is the QALY breakdown of the reviewed therapies:
- Haegarda – $243,000 per QALY;
- Cinryze – $5,870,000 per QALY; and
- Lanadelumab – $1,020,000 per QALY.